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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idSudden respiratory muscle paralysis and apnea in a patient
infected with multidrug-resistant Pseudomonas aeruginosa
treated with intravenous colistin
The mounting prevalence worldwide of infections due to
multidrug-resistant Gram-negative bacilli has renewed interest in
colistin, an antibiotic that was progressively abandoned during the
1970s due to signiﬁcant renal and neurological toxicity.1
Respiratory failure with colistin use was reported in the years
following its release; however, there are only two recent reports of
colistin-induced respiratory failure, occurring on days 5 and 18 of
treatment, respectively.2,3 We report a case of neurotoxicity
manifesting as apnea and respiratory failure associated with
intravenous colistimethate sodium (CMS).
The case was a 75-year-old man, weighing 85 kg, who was
scheduled for an ileostomy closure following an anterior rectum
resection (due to colorectal cancer) 1 year ago, which was
complicated with fecal peritonitis and severe septic shock
secondary to an anastomotic leak. His medical history included
arterial hypertension and dyslipidemia. On day 8 post-surgery
the patient developed an anastomotic leak and an intra-
abdominal infection of Pseudomonas aeruginosa resistant to all
antimicrobials except aztreonam (minimum inhibitory concen-
tration (MIC) 16 mg/ml (moderately susceptible)) and colistin
(MIC 2 mg/ml). Therapy was instituted with intravenous colistin
(3 million international units every 8 h). The estimated
creatinine clearance was 90 ml/min.
After 36 h of intravenous CMS, the patient developed rapidly
progressive weakness with dyspnea, tachypnea, and ﬂaccid
paralysis of both upper extremities, as well as several episodes
of hypocalcemia, which was treated with an intravenous calcium
gluconate bolus. The possibility that this was CMS-induced was not
suspected until 12 h after the morning dose of colistin was given,
when the patient suddenly became apneic, necessitating an urgent
endotracheal intubation.
Colistin treatment was abandoned and the patient was
started on aztreonam and amikacin therapy, under mechanical
ventilation and continuous hemoﬁltration. The patient’s clinical
course was further complicated by the development of fungal
sepsis and progressive cardiovascular dysfunction, and he died
24 h later.1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.11.013The proposed mechanism of colistin neurotoxicity is a non-
competitive myoneuronal presynaptic blockade of acetylcholine
release. However, hypocalcemia-induced prolongation of depolar-
ization may also play a role.4 Recent reports have not described
neurotoxicity associated with intravenous CMS, with the exception
of cases in the cystic ﬁbrosis population, among whom neurotox-
icity has manifested as paresthesias and ataxia in 29% of patients
treated; all patients received intravenous dosages in excess of
5 mg/kg per day.5 Our patient received intravenous CMS dosages of
160 mg every 8 h, equivalent to approximately 6 mg/kg per day.
In our opinion, the establishment of any relationships between
the daily dosage of CMS, colistin levels, and neurological events is
needed, especially in the critically ill patient population.
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